Multiple Sclerosis Clinical Trials in Houston

Showing 241-260 of 517 trials

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

NCT02872701

This is a phase 2, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/positron emission tomography imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near Infrared Imaging (NIR) at identifying pulmonary nodules within the operating theater, and to assess the safety and tolerability of single intravenous doses of OTL38.

Lung NeoplasmsLung Cancer

On Target Laboratories, LLC100 participantsStarted May 2017

Boston, Massachusetts, United States • Cleveland, Ohio, United States • Philadelphia, Pennsylvania, United States +3 more locations

COMPLETEDPhase 3< 1 mile

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03038100

This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.

Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms

Hoffmann-La Roche1,301 participantsStarted Mar 2017

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Tucson, Arizona, United States +265 more locations

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Multiple Sclerosis Trials in Other Cities

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

Utility of OverStitch Sx After ESD

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

An Extension of the TG1101-RMS201 Trial

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Other Conditions in Houston